Literature DB >> 10899026

DNA vaccines: a key for inducing long-term cellular immunity.

S Gurunathan1, C Y Wu, B L Freidag, R A Seder.   

Abstract

Over the past few years, major advances in several areas of immunology have provided a foundation for the rational design of vaccines against diseases requiring cellular immunity. Among these advances are the cellular mechanisms by which DNA vaccines can sustain long-term humoral and cellular immunity.

Mesh：

Substances：

Year:  2000        PMID： 10899026     DOI： 10.1016/s0952-7915(00)00118-7

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  64 in total

1.  Mycobacterium hsp65 DNA entrapped into TDM-loaded PLGA microspheres induces protection in mice against Leishmania (Leishmania) major infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Karla de Melo Lima; Célio Lopes Silva; José Maciel Rodrigues; Ana Paula Fernandes
Journal:  Parasitol Res       Date:  2006-01-24       Impact factor: 2.289

2.  The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells.

Authors:  Godwin Nchinda; Janelle Kuroiwa; Margarita Oks; Christine Trumpfheller; Chae Gyu Park; Yaoxing Huang; Drew Hannaman; Sarah J Schlesinger; Olga Mizenina; Michel C Nussenzweig; Klaus Uberla; Ralph M Steinman
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

3.  Protective immunity induced by a DNA vaccine-encoding Toxoplasma gondii microneme protein 11 against acute toxoplasmosis in BALB/c mice.

Authors:  Qing Tao; Rui Fang; Weichao Zhang; Yifan Wang; Jianxi Cheng; Yalin Li; Kun Fang; Muhammad Kasib Khan; Min Hu; Yanqin Zhou; Junlong Zhao
Journal:  Parasitol Res       Date:  2013-06-10       Impact factor: 2.289

4.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.

Authors:  Toshio Naito; Yutaro Kaneko; Danuta Kozbor
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

5.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice.

Authors:  Francisco M Teixeira; Henrique C Teixeira; Ana Paula Ferreira; Michele F Rodrigues; Vasco Azevedo; Gilson C Macedo; Sergio C Oliveira
Journal:  Clin Vaccine Immunol       Date:  2006-08

7.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

8.  Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.

Authors:  Blaise Dondji; Eszter Deak; Karen Goldsmith-Pestana; Eva Perez-Jimenez; Mariano Esteban; Sachiko Miyake; Takashi Yamamura; Diane McMahon-Pratt
Journal:  Eur J Immunol       Date:  2008-03       Impact factor: 5.532

9.  Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells.

Authors:  Tarvo Rajasalu; Helen Brosi; Cornelia Schuster; Andreas Spyrantis; Bernhard Otto Boehm; Lieping Chen; Jörg Reimann; Reinhold Schirmbeck
Journal:  Diabetes       Date:  2010-05-18       Impact factor: 9.461

10.  DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.

Authors:  Uta G Lange; Pietro Mastroeni; Jenefer M Blackwell; Carmel B Stober
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.